$4.77 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$6.6 MillionTotal revenue in the last quarter.
-$42.2 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
-$2.40Earnings per share is the amount of net income that is attributed to each single share outstanding.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-35.55xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-42.4 MillionEarnings before interest expenses and taxes in the last quarter.
0The number of full time employees.
Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.
Vertex, Intellia Therapeutics: Gene Modifying Shares To Watch | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex NewsFXNews24, 2 months ago
Intellia Therapeutics, Inc. (NASDAQ:NTLA) CEO John M. Leonard sold 109,889 shares of the firm’s stock in a transaction dated Monday, February 1st. The shares were sold at an average price of $64.00...Watchlist News, 3 months ago
Raymond James Stick to Their Buy Rating for Intellia TherapeuticsInvesting.com, 3 months ago